Thomas Nagy, former director of the Novo Nordisk Foundation and founder of the BioInnovation Institute, has joined agtech impact investor Astanor Ventures as an operational partner.
The fund will invest in early-stage agriculture and food value-chain companies pursuing environmental and social causes.
Nagy’s experience facilitating start-ups throughout his career – and particularly through the Novo Nordisk Foundation’s BioInnovation Institute – will benefit Astanor’s portfolio companies, the firm said in a statement.
Nagy spent almost 30 years with the Novo Group, where he gained extensive experience in operations, management and business development.
At the Novo Group’s biotechnology research arm, Novozymes, Nagy served as president of its North American business before leading the company’s stakeholder relations and then its global supply chain operations.
In his new role with Astanor, Nagy will play a central role in pre-investment assessments as well as post-investment portfolio operational support, the firm said.
Astanor Ventures co-founder and partner Eric Archambeau said he was confident Nagy’s contribution would boost the investor’s ability to make an impact. “His wealth of experience and deep insights into the life sciences and industrial biotechnology industries will be instrumental in our mission to invest in and support companies that are addressing some of the world’s most pressing challenges.”
Nagy said he was excited to contribute to Astanor’s mission. “With a deep-rooted commitment to sustainable solutions, Astanor Ventures has already made significant strides, and I am eager to leverage my industry experience to further drive positive impact and support the growth of transformative companies.
“Together, we can make a meaningful difference in shaping the future of sustainable food production and global supply chains.”
Nagy will work part-time for Astanor from Copenhagen and continues to serve on the board of several biotech companies in Denmark and abroad.